News | Coronavirus (COVID-19) | March 31, 2020

Cardiologists Head COVID-19 Trial Collaboration in Detroit Area Hospitals

Effort will pool coronavirus patients from several centers for clinical trials, based on previous collaboration they did for Detroit Cariogenic Shock Initiative

William O’Neill, M.D., Henry Ford Hospital, speaking at the announcement of the creation of the Cardiogenic Shock Initiative in 2016. O'Neill asked the same partner hospitals in the Detroit area to pool resources to create a COVID-19 study group to help speed the gathering of data in COVID-19 drug trials.

William O’Neill, M.D., Henry Ford Hospital, speaking at the announcement of the creation of the Cardiogenic Shock Initiative in 2016. O'Neill asked the same partner hospitals in the Detroit area to pool resources to create a COVID-19 study group to help speed the gathering of data in COVID-19 drug trials.

March 31, 2020 — Four metropolitan Detroit hospital systems and a leading research university announced a collaboration to bring large-scale novel coronavirus (COVID-19, SARS-CoV-2) drug trials to southeast Michigan.

Doctors from Henry Ford Health System, Ascension Michigan, Beaumont, Detroit Medical Center and Wayne State University are teaming up to form the study group. Doctors affiliated with the five organizations collectively treat millions of patients a year, which provides a large-scale study opportunity for potentially life-saving treatment options.

“The whole idea is we want to collaborate in the region, apply for the new trials and be part of discovering best practices and treatments for COVID-19,” said Henry Ford Health System interventional cardiologist William  O’Neill, M.D., who organized the collaboration. “We’re going to be very competitive. We want to figure out how to optimally treat these patients, to establish protocols and systems so we can all do things effectively and, very importantly, to quickly track outcomes.”

Cardiologists Shukri David, M.D., from Ascension and Amr Abbas, M.D., from Beaumont, and emergency department specialist Brian O’Neil, M.D., from DMC are leading their respective health systems’ efforts, along with emergency department specialist Phil Levy, M.D, FAHA, FACC, from Wayne State University. 

"This viral pandemic has no boundaries,” said David, chair of cardiovascular services, Ascension Michigan. “By combining the resources of our medical community, we will offer research opportunities that no one institution alone can defeat. Our efforts are stronger when we work together.”

Collaboration Already in Place From Detroit Cariogenic Shock Initiative

Their collaboration to save lives is not new. In 2016, led by O’Neill, the cardiologists joined forces for an initiative to lower the death rate from cardiogenic shock, a potentially fatal side effect of massive heart attacks. Together in the Detroit cariogenic Shock Initative, they showed a specific treatment protocol increased patient survival in southeast Michigan from 50% to more than 70%. The protocol is now the basis for the National Cardiogenic Shock Initiative, used by cardiologists to save lives across the United States.

When COVID-19 hit, O’Neill, medical director of the Henry Ford Center for Structural Heart Disease, reached out to the others and Henry Ford leadership. He suggested they use that previous collaborative experience to quickly mobilize against this new threat – and together bring randomized, controlled trials to southeast Michigan.

“We moved the needle on survival in cardiogenic shock for the first time in 20 years with our collaboration then,” said emergency department specialist Brian O’Neil from DMC and WSU, who is not related.  “We hope to replicate that success on a much larger scale in our battle with COVID-19 today and support our colleagues who are on the front lines.”


Hope to Start COVID-19 Trials in Detroit Area Soon

The COVID-19 collaborators are working directly in support of infectious disease experts at their respective hospitals. They hope to receive National Institutes of Health approval to bring two specific COVID-19 trials to southeast Michigan:

1. Moderna’s COVID-19 vaccine: The company’s chief executive officer said Moderna may provide the vaccine to a few people, which could include healthcare workers, as early as this fall. A healthy volunteer received the first COVID-19 vaccine March 16. The company estimates it could take 18 months to make it commercially available, if the trials prove successful.

2. Takeda’s hyperimmune globulin: Using plasma from patients who have recovered from COVID-19, the company is evaluating a treatment that’s effective on other severe acute viral respiratory infections. 

“Big research studies need time, but they also need a certain number of patients to prove the new treatment is number one: feasible; number two: effective; number three: safe,” said Dr. Abbas, an interventional and structural cardiologist who is the director of Cardiovascular Research Program at Beaumont Hospital, Royal Oak. “For us to reach that perfect scenario, we need collaboration on that level among our hospital systems.”

Once trials are initiated at health systems, participation takes place through the patients’ treating physicians. 

“We hope our work here will last well into the future, should COVID-19 continue to be a threat,” said Levy, chief innovation officer of the Wayne State University Physician Group and assistant vice president of translational science and clinical eesearch innovation for Wayne State University. “By combining forces, we can marshal greater research capabilities to effectively test vaccines and treatments to combat this virus.”

More information on particular trials underway in the United States can be found at

First Large-scale U.S. Study on Hydroxychloroquine COVID-19 Prophylaxis Begins in Detroit

Watch an interview with O'Neill on the trials in the VIDEO: Trial Tests if Hydroxychloroquine Can Protect Healthcare Workers from COVID-19 

FDA rejects Henry Ford system's bid for hydroxychloroquine approval

Find videos and articles on Henry Ford Hospital's cardiology program


Related Content

News | Coronavirus (COVID-19)

March 20, 2024 — SARS-CoV-2, the virus that causes COVID-19, can damage the heart even without directly infecting the ...

Home March 20, 2024
News | Coronavirus (COVID-19)

January 25, 2024 — New research confirms what public health leaders have been fearing: the significant uptick in the ...

Home January 25, 2024
News | Coronavirus (COVID-19)

January 11, 2024 — Acute cardiovascular manifestations of COVID-19, such as heart failure, thrombosis, and dysrhythmia ...

Home January 11, 2024
News | Coronavirus (COVID-19)

December 14, 2023 — Individuals infected with COVID-19 are also at an increased risk of suffering from heart rhythm ...

Home December 14, 2023
News | Coronavirus (COVID-19)

October 16, 2023 — A door-to-balloon (D2B) time of 90-minutes or less is associated with improved outcomes for heart ...

Home October 16, 2023
News | Coronavirus (COVID-19)

October 11, 2023 — Unvaccinated people who have recovered from COVID-19 are at heightened risk of heart complications ...

Home October 11, 2023
News | Coronavirus (COVID-19)

September 26, 2023 — New research from the Smidt Heart Institute at Cedars-Sinai shows that patients who went to a ...

Home September 26, 2023
News | Coronavirus (COVID-19)

June 19, 2023 — Patients who had heart attacks during the first COVID-19 lockdown in the UK and Spain are predicted to ...

Home June 19, 2023
News | Coronavirus (COVID-19)

June 14, 2023 — A University of Waterloo engineer’s MRI invention reveals better than many existing imaging technologies ...

Home June 14, 2023
News | Coronavirus (COVID-19)

June 9, 2023 — Patients infected with beta and delta COVID-19 variants, and those who required hospital stays for COVID ...

Home June 09, 2023
Subscribe Now